KR20220003537A - Jak1 선택적 키나제 억제제 - Google Patents
Jak1 선택적 키나제 억제제 Download PDFInfo
- Publication number
- KR20220003537A KR20220003537A KR1020217036576A KR20217036576A KR20220003537A KR 20220003537 A KR20220003537 A KR 20220003537A KR 1020217036576 A KR1020217036576 A KR 1020217036576A KR 20217036576 A KR20217036576 A KR 20217036576A KR 20220003537 A KR20220003537 A KR 20220003537A
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- equiv
- amino
- alkyl
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/083376 | 2019-04-19 | ||
| CN2019083376 | 2019-04-19 | ||
| PCT/CN2020/085338 WO2020211839A1 (en) | 2019-04-19 | 2020-04-17 | Jak1 selective kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220003537A true KR20220003537A (ko) | 2022-01-10 |
Family
ID=72837031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217036576A Ceased KR20220003537A (ko) | 2019-04-19 | 2020-04-17 | Jak1 선택적 키나제 억제제 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12606544B2 (https=) |
| EP (1) | EP3956322B1 (https=) |
| JP (1) | JP7555959B2 (https=) |
| KR (1) | KR20220003537A (https=) |
| CN (1) | CN113710664B (https=) |
| AR (1) | AR118729A1 (https=) |
| AU (1) | AU2020258619C1 (https=) |
| BR (1) | BR112021020964A2 (https=) |
| CA (1) | CA3134174A1 (https=) |
| DK (1) | DK3956322T3 (https=) |
| ES (1) | ES3031576T3 (https=) |
| MX (1) | MX2021012749A (https=) |
| PT (1) | PT3956322T (https=) |
| TW (1) | TWI910107B (https=) |
| WO (1) | WO2020211839A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024009215A1 (en) * | 2022-07-05 | 2024-01-11 | Dong-A St Co., Ltd. | Novel compounds as gcn2 inhibitors, pharmaceutical compositions and uses thereof |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022111499A1 (zh) * | 2020-11-26 | 2022-06-02 | 深圳铂立健医药有限公司 | 一种酰胺化合物、药物组合物及其应用 |
| CN114380806B (zh) * | 2022-03-24 | 2022-06-10 | 中国药科大学 | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 |
| EP4554931A1 (en) * | 2022-07-12 | 2025-05-21 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198900B2 (en) * | 2011-11-10 | 2015-12-01 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment of peritoneal injury using JAK inhibitors |
| JP6767491B2 (ja) | 2015-09-25 | 2020-10-14 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | Ｊａｋを阻害するための化合物及び方法 |
| ES2938648T3 (es) * | 2017-01-17 | 2023-04-13 | Astrazeneca Ab | Inhibidores selectivos de JAK1 |
| CA3113732C (en) * | 2018-09-21 | 2023-07-11 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Aromatic heterocyclic compound with kinase inhibitory activity |
-
2020
- 2020-04-17 MX MX2021012749A patent/MX2021012749A/es unknown
- 2020-04-17 AR ARP200101101A patent/AR118729A1/es unknown
- 2020-04-17 JP JP2021561927A patent/JP7555959B2/ja active Active
- 2020-04-17 CN CN202080029899.3A patent/CN113710664B/zh active Active
- 2020-04-17 WO PCT/CN2020/085338 patent/WO2020211839A1/en not_active Ceased
- 2020-04-17 BR BR112021020964A patent/BR112021020964A2/pt unknown
- 2020-04-17 KR KR1020217036576A patent/KR20220003537A/ko not_active Ceased
- 2020-04-17 CA CA3134174A patent/CA3134174A1/en active Pending
- 2020-04-17 ES ES20790639T patent/ES3031576T3/es active Active
- 2020-04-17 AU AU2020258619A patent/AU2020258619C1/en active Active
- 2020-04-17 EP EP20790639.7A patent/EP3956322B1/en active Active
- 2020-04-17 US US17/604,442 patent/US12606544B2/en active Active
- 2020-04-17 TW TW109112994A patent/TWI910107B/zh active
- 2020-04-17 PT PT207906397T patent/PT3956322T/pt unknown
- 2020-04-17 DK DK20790639.7T patent/DK3956322T3/da active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024009215A1 (en) * | 2022-07-05 | 2024-01-11 | Dong-A St Co., Ltd. | Novel compounds as gcn2 inhibitors, pharmaceutical compositions and uses thereof |
| US12240836B2 (en) | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022529061A (ja) | 2022-06-16 |
| JP7555959B2 (ja) | 2024-09-25 |
| EP3956322A4 (en) | 2023-05-03 |
| US20220220096A1 (en) | 2022-07-14 |
| EP3956322A1 (en) | 2022-02-23 |
| ES3031576T3 (en) | 2025-07-09 |
| AU2020258619A1 (en) | 2021-09-16 |
| MX2021012749A (es) | 2021-11-18 |
| CA3134174A1 (en) | 2020-10-22 |
| WO2020211839A1 (en) | 2020-10-22 |
| CN113710664A (zh) | 2021-11-26 |
| CN113710664B (zh) | 2024-01-26 |
| AU2020258619C1 (en) | 2026-01-29 |
| AU2020258619B2 (en) | 2025-10-23 |
| TWI910107B (zh) | 2026-01-01 |
| US12606544B2 (en) | 2026-04-21 |
| DK3956322T3 (da) | 2025-06-16 |
| PT3956322T (pt) | 2025-06-04 |
| TW202104215A (zh) | 2021-02-01 |
| AR118729A1 (es) | 2021-10-27 |
| EP3956322B1 (en) | 2025-05-14 |
| BR112021020964A2 (pt) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10556908B2 (en) | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | |
| US12606544B2 (en) | JAK1 selective kinase inhibitor | |
| ES2737696T3 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| JP6800969B2 (ja) | 呼吸器疾患の処置のためのｊａｋキナーゼ阻害剤化合物 | |
| KR20200096571A (ko) | 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물 | |
| US20130040933A1 (en) | Azaindoles as janus kinase inhibitors | |
| KR20160018567A (ko) | 키나아제 억제제 | |
| KR20160015221A (ko) | 키나아제 억제제 | |
| KR20160016973A (ko) | P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체 | |
| US9096598B2 (en) | Azaindoles as Janus kinase inhibitors | |
| RU2818002C2 (ru) | Селективный ингибитор киназы JAK1 | |
| HK40055987A (en) | Jak1 selective kinase inhibitor | |
| US11230547B2 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta | |
| HK40055987B (zh) | Jak1选择性激酶抑制剂 | |
| HK1258929B (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
| HK1258929A1 (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
| HK1234392A1 (en) | Pyrazolopyridines and pyrazolopyrimidines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |